Dyax Corp. Appoints Marc Kozin to Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for
unmet medical needs, announced today the appointment of Marc Kozin to
its Board of Directors.
"Marc brings to our Board nearly 30 years of domestic and international
experience in strategy consulting and a deep understanding of our
industry," said Henry E. Blair, Chairman of Dyax's Board of Directors.
"His expertise and record of success in advising life sciences companies
will provide the Board with a new and valued perspective as we continue
to grow our KALBITOR® (ecallantide) business, expand our
angioedema portfolio and leverage our Licensing and Funded Research
Program."
For 15 years, Mr. Kozin was North American President of L.E.K.
Consulting, a global management consulting firm that uses deep industry
expertise and analytical rigor to help clients solve their most
critical business problems. Mr. Kozin led the development of L.E.K.'s
biopharmaceutical & life sciences practice, where he advised
biopharmaceutical leaders on strategic issues facing their
organizations, including, acquisition opportunities and target
screening, licensing and joint ventures, portfolio optimization, product
planning and commercialization, and domestic and global marketing
strategies. Mr. Kozin also serves on the boards of Endocyte, Medical
Simulation Corporation, UFP Technologies, CrunchTime! Information
Systems, Inc. and DukeEngage.
Mr. Kozin received his B.A., magna cum laude, in Economics from Duke
University and an M.B.A. with distinction from The Wharton School of the
University of Pennsylvania.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the
discovery, development and commercialization of novel biotherapeutics
for unmet medical needs. The Company's key value drivers are the KALBITOR®
(ecallantide) business and the Angioedema Portfolio, as well as
the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, the Company
has been selling it in the United States for the treatment of acute
attacks of hereditary angioedema (HAE) in patients 16 years of age and
older. Outside the United States, the Company has established
partnerships to obtain regulatory approval for and commercialization of
KALBITOR in certain markets and is evaluating opportunities in others.
The Company is currently developing products to expand its angioedema
portfolio, including a diagnostic strategy to identify plasma kallikrein
(bradykinin) mediated (PKM) angioedema and a therapeutic candidate,
DX-2930, for the prophylactic treatment of PKM angioedema.
KALBITOR and DX-2930 were identified using Dyax's patented phage display
technology, which rapidly selects compounds that bind with high affinity
and specificity to therapeutic targets. Dyax leverages this technology
broadly through the LFRP. This program has provided the Company a
portfolio of product candidates being developed by its licensees.
Dyax is headquartered in Burlington, Massachusetts. For additional
information about Dyax, please visit www.dyax.com.
Disclaimer
This press release contains forward-looking statements. Statements that
are not historical facts are based on Dyax's current expectations,
beliefs, assumptions, estimates, forecasts and projections about the
industry and markets in which Dyax and its licensees compete. The
statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and assumptions,
which are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed in such forward-looking
statements because of uncertainties involved in any future projections,
as well as uncertainties associated with various activities and aspects
of Dyax's business. These risks and uncertainties are described or
referred to in Item 1A, "Risk Factors" in Dyax's most recent Annual
Report on Form 10-K and other periodic reports filed with the Securities
and Exchange Commission. Dyax cautions investors not to place undue
reliance on the forward-looking statements contained in this release.
These statements speak only as of the date of this release, and Dyax
undertakes no obligations to update or revise these statements, except
as may be required by law.
Dyax, the Dyax logo, and KALBITOR are registered trademarks of Dyax Corp.
Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director
Investor
Relations and Corporate Communications
jrobinson@dyax.com
Source: Dyax Corp.
News Provided by Acquire Media
Close window | Back to top
